Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Alessandro Cherubini, Elia Casirati, Melissa Tomasi, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 12, pp. 1033-1043
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 207
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 62
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
Alessandro Cherubini, Mahnoosh Ostadreza, Oveis Jamialahmadi, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2643-2655
Open Access | Times Cited: 56
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
Alessandro Cherubini, Sara Della Torre, Serena Pelusi, et al.
Trends in Molecular Medicine (2024)
Closed Access | Times Cited: 21
MASH clinical trials and drugs pipeline: An impending tsunami
Mazen Noureddin
Hepatology (2024)
Closed Access | Times Cited: 18
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 15
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 14
LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases
Genshan Zhang, Wei Jiang, Fangxun He, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 10
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Shahid Habib
World Journal of Gastrointestinal Pathophysiology (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 10
Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 34
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, et al.
Liver International (2023) Vol. 43, Iss. 5, pp. 975-988
Open Access | Times Cited: 17
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Microplastic-induced NAFLD: Hepatoprotective effects of nanosized selenium
Qi Shen, Yun Jie Liu, Tian Qiu, et al.
Ecotoxicology and Environmental Safety (2024) Vol. 272, pp. 115850-115850
Open Access | Times Cited: 6
Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle‐aged individuals with metabolic dysfunction
Alessandro Mantovani, Serena Pelusi, Sara Margarita, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 10, pp. 1093-1102
Open Access | Times Cited: 15
PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction
Yusong Gou, Lifei Wang, Jinhan Zhao, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9681-9681
Open Access | Times Cited: 14
Advances in genetic variation in metabolism-related fatty liver disease
Fan Shi, Mei Zhao, Shudan Zheng, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 11
The lack of apoA-I in apoE-KO mice affects the liver transcriptome
Elsa Franchi, A. Colombo, Stefano Manzini, et al.
Nutrition Metabolism and Cardiovascular Diseases (2025), pp. 103920-103920
Open Access
Deciphering Significances of Autophagy in the Development and Metabolism of Adipose Tissue
Zitao Liu, Haoyuan Peng, Pengfei Liu, et al.
Experimental Cell Research (2025), pp. 114478-114478
Closed Access
Association between IGF1 rs5742612 Polymorphism and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease
于蕾 林
Advances in Clinical Medicine (2025) Vol. 15, Iss. 02, pp. 1636-1645
Closed Access
Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD
Giovanna Mercurio, Antonia Giacco, Nicla Scopigno, et al.
Nutrients (2025) Vol. 17, Iss. 7, pp. 1214-1214
Open Access
Evaluation of Metabolic Dysfunction-Associated Fatty Liver Disease-Related Pathogenic Mechanisms in Human Steatotic Liver Cell-Based Model: Beneficial Effects of Prunus domestica L. subsp. syriaca Extract
Laura Comi, Claudia Giglione, Fationa Tolaj, et al.
Nutrients (2025) Vol. 17, Iss. 7, pp. 1249-1249
Open Access
Experimental Models to Investigate PNPLA3 in Liver Steatosis
Alireza Ramandi, Anna‐Mae Diehl, Danny Issa, et al.
Liver International (2025) Vol. 45, Iss. 5
Closed Access
Page 1 - Next Page

Scroll to top